Clozapine

Red

Brand Name(s):

Indication:Schizophrenia, psychosis in PD

Rationale:1,2,3

Considered:Jun-09

Review Date:Oct-25

Comments:
Drug Safety Update – Monitoring blood toxicity levels is advised in certain clinical situations: stopping smoking/switching to e-cigarettes, concomitant use of medicines which may cause interactions, pneumonia or other serious infections, if poor/reduced clozapine metabolism or toxicity is suspected. August 2020. …………………………Drug Safety Update
Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus
Oct 2017
…………………………
Updated NICE CG155
Psychosis and schizophrenia in children and young people: recognition and management
Oct 2016
…………………………
NICE CG178
Psychosis and schizophrenia in adults: treatment and management
Full details at:https://www.nice.org.uk/guidance/cg178/resources/guidance-psychosis-and-schizophrenia-in-adults-treatment-and-management-pdf
Feb 2014
…………………………
Psychosis and schizophrenia in adults:
National Clinical Guideline Number CG178
February 2014
http://guidance.nice.org.uk/CG178/NICEGuidance/pdf/English

Psychosis and schizophrenia in children and young people
National Clinical Guideline Number CG155
January 2013
Guidance available at: http://www.nice.org.uk/nicemedia/live/14021/62392/62392.pdf
…………………………
Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009